1
|
Lin X, Duan X, Jacobs C, Ullmann J, Chan CY, Chen S, Cheng SH, Zhao WN, Poduri A, Wang X, Haggarty SJ, Shi P. High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology. Nat Commun 2018; 9:5142. [PMID: 30510233 PMCID: PMC6277389 DOI: 10.1038/s41467-018-07289-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Accepted: 10/23/2018] [Indexed: 12/19/2022] Open
Abstract
Technologies for mapping the spatial and temporal patterns of neural activity have advanced our understanding of brain function in both health and disease. An important application of these technologies is the discovery of next-generation neurotherapeutics for neurological and psychiatric disorders. Here, we describe an in vivo drug screening strategy that combines high-throughput technology to generate large-scale brain activity maps (BAMs) with machine learning for predictive analysis. This platform enables evaluation of compounds’ mechanisms of action and potential therapeutic uses based on information-rich BAMs derived from drug-treated zebrafish larvae. From a screen of clinically used drugs, we found intrinsically coherent drug clusters that are associated with known therapeutic categories. Using BAM-based clusters as a functional classifier, we identify anti-seizure-like drug leads from non-clinical compounds and validate their therapeutic effects in the pentylenetetrazole zebrafish seizure model. Collectively, this study provides a framework to advance the field of systems neuropharmacology. A major goal in neuropharmacology is to develop new tools to effectively test the therapeutic potential of pharmacological agents to treat neurological and psychiatric conditions. Here, authors present an in vivo drug screening system that generates large-scale brain activity maps to be used with machine learning to predict the therapeutic potential of clinically relevant drug leads.
Collapse
Affiliation(s)
- Xudong Lin
- Department of Biomedical Engineering, City University of Hong Kong, 999077, Kowloon, Hong Kong SAR, China
| | - Xin Duan
- Department of Biomedical Science, City University of Hong Kong, 999077, Kowloon, Hong Kong SAR, China
| | - Claire Jacobs
- Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Department of Neurology, Harvard Medical School, Boston, MA, 02114, USA
| | - Jeremy Ullmann
- Epilepsy Genetics Program and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Department of Neurology, Harvard Medical School, Boston, MA, 02115, USA
| | - Chung-Yuen Chan
- Department of Biomedical Engineering, City University of Hong Kong, 999077, Kowloon, Hong Kong SAR, China
| | - Siya Chen
- Department of Biomedical Engineering, City University of Hong Kong, 999077, Kowloon, Hong Kong SAR, China
| | - Shuk-Han Cheng
- Department of Biomedical Science, City University of Hong Kong, 999077, Kowloon, Hong Kong SAR, China
| | - Wen-Ning Zhao
- Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Department of Neurology, Harvard Medical School, Boston, MA, 02114, USA
| | - Annapurna Poduri
- Epilepsy Genetics Program and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Department of Neurology, Harvard Medical School, Boston, MA, 02115, USA
| | - Xin Wang
- Department of Biomedical Science, City University of Hong Kong, 999077, Kowloon, Hong Kong SAR, China. .,Shenzhen Research Institute, City University of Hong Kong, 518057, Shenzhen, China.
| | - Stephen J Haggarty
- Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Department of Neurology, Harvard Medical School, Boston, MA, 02114, USA.
| | - Peng Shi
- Department of Biomedical Engineering, City University of Hong Kong, 999077, Kowloon, Hong Kong SAR, China. .,Shenzhen Research Institute, City University of Hong Kong, 518057, Shenzhen, China.
| |
Collapse
|
2
|
Vecht C, Duran-Peña A, Houillier C, Durand T, Capelle L, Huberfeld G. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol 2017; 133:603-607. [PMID: 28492978 DOI: 10.1007/s11060-017-2473-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Accepted: 05/07/2017] [Indexed: 11/27/2022]
Abstract
Drug-resistant epilepsy (DRE) occurs commonly in gliomas, possibly due to a shared mechanism of AMPA-activation involving both seizure activity and tumor growth. We tested the AMPA-receptor blocker perampanel (PER) in patients with DRE in low- and high-grade gliomas. Seizure response was defined as 50% drop in seizure frequency or as seizure-freedom. Cognitive function was examined by computerized test on cognitive speed (CTCS), which is sensitive to the type of cognitive dysfunction associated with epilepsy and use of anticonvulsants. Treatment policy included reduction of dose or discontinuation of one or more concurrent AEDs, once a seizure-free response was observed. Twelve patients were included patients, median age 41 years, 9 men versus 3 women and 6 months median duration of follow-up. An objective seizure response (75%) was observed in 9 (75%) out of 12 patients: 50%-seizure response in 3, seizure-freedom in 6, which is plainly more than seen with other types of DRE. Side-effects occurred in six patients. Cognitive function as examined by CTCS improved in six out of eight associated withlowering of concurrent AEDs. The final median dose of PER was 8 mg (varying between 2 and 12 mg). These results of an objective seizure response in 9 (75%) out of 12 patients treated by PER in DRE may be interpreted as a surrogate-marker of tumor response secondary to AMPA blockade, advancing confirmation by MR imaging. These results warrant further study of PER on tumor activity in gliomas.
Collapse
Affiliation(s)
- Charles Vecht
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France. .,Service Neurologie Mazarin, CHU Pitié-Salpêtrière, Paris, 47 Bld. de l´Hopital, 75651, PARIS CEDEX 13, France.
| | - Alberto Duran-Peña
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Caroline Houillier
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Thomas Durand
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Laurent Capelle
- Neurosurgery Babinski, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Gilles Huberfeld
- Pitié-Salpêtrière Hospital, and Laboratory of Neurophysiology, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| |
Collapse
|